WeightWatchers reported total revenues of $172 million for Q3 2025, a decline of 10.8% year-over-year. Despite a net loss of $58 million, primarily due to a significant income tax charge, the company achieved a robust Adjusted EBITDA of $43 million, reflecting disciplined cost management. Clinical Subscription Revenue showed strong growth of 35.3% year-over-year, and the company's balance sheet was significantly strengthened post-restructuring with total debt reduced by over 70%.
Total Revenues for Q3 2025 were $172 million, a 10.8% decrease year-over-year.
Net Loss for the quarter was $58 million, impacted by a $53 million income tax expense.
Clinical Subscription Revenues grew by 35.3% year-over-year, reaching $26 million.
Adjusted EBITDA was $43 million, with an Adjusted EBITDA Margin of 24.9%, demonstrating strong profitability and cost discipline.
WeightWatchers is narrowing its full-year fiscal 2025 guidance to the higher end of previous ranges for both Revenues and Adjusted EBITDA, reflecting confidence in its strategic execution and financial performance.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance